Guest Editor: Rajiv Agarwal: Cardiovascular Risk Profile Assessment and Medication Control Should Come First

@article{Zoccali2007GuestER,
  title={Guest Editor: Rajiv Agarwal: Cardiovascular Risk Profile Assessment and Medication Control Should Come First},
  author={Carmine Zoccali and Francesca Romana Mallamaci and Giovanni Tripepi},
  journal={Seminars in Dialysis},
  year={2007},
  volume={20}
}
1. Coresh J, Wei GL, McQuillan G, et al.: Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health andNutrition Examination Survey (1988-1994).Arch InternMed 161:1207–1216, 2001 2. Agarwal R, Nissenson AR, Batlle D, et al.: Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. AmJMed 115:291–297, 2003 3. Agarwal R, Lewis RR: Prediction of hypertension in chronic… 
Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes controversies conference.
TLDR
This report summarizes the deliberations and recommendations of a conference sponsored by the Kidney Disease: Improving Global Outcomes (KDIGO) to address the following questions: what is the optimal BP treatment target in relation to end-organ damage and outcomes in dialysis patients; how should antihypertensive drugs be used in dial renal patients; and what nonpharmacological therapies can be considered in achieving BP targets.
How should hypertension be assessed and managed in hemodialysis patients? Home BP, not dialysis unit BP, should be used for managing hypertension.
  • R. Agarwal
  • Medicine, Biology
    Seminars in dialysis
  • 2007
TLDR
Outof-office BP measurement techniques in the management of patients on hemodialysis suggest that self-measured BP (home BP) recordings and ambulatory BP recordings reduce misclassification of hypertension and increase the ability to predict renal and cardiovascular events in patients with CKD.

References

SHOWING 1-10 OF 27 REFERENCES
Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis.
TLDR
Pulse pressure is associated with risk of death in a large, nationally representative sample of patients undergoing maintenance hemodialysis and the recognition of pulse pressure as an important correlate of mortality in patients receiving dialysis highlights the need to investigate the relationship between potential therapeutic implications of conduit vessel function and clinical outcomes in patients with end-stage renal disease.
Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis.
Blood pressure control in dialysis patients: importance of the lag phenomenon.
Prognostic value of 24-hour ambulatory blood pressure monitoring and of night/day ratio in nondiabetic, cardiovascular events-free hemodialysis patients.
TLDR
The results suggest that the night/day systolic ratio and LVH provide overlapping prognostic information, a phenomenon in keeping with the hypothesis that they represent a common pathway leading to adverse outcomes in ESRD.
What is hypertension in chronic haemodialysis? The role of interdialytic blood pressure monitoring.
  • S. Mitra, S. Chandna, K. Farrington
  • Medicine, Biology
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 1999
TLDR
Ambulatory monitoring has a role in evaluating persistent poor blood pressure control in haemodialysis patients andWalk-in predialysis pressures overestimate mean interdialytic pressures due to a high incidence of white-coat effect, which shows some habituation with time on dialysis.
Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies.
TLDR
Trends were observed suggesting fosinopril may be associated with a lower risk of CVEs, and trends may have become statistically significant had the sample size been larger, and these findings warrant further study.
Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease
TLDR
In the setting of coronary care unit admission for CHF and ACS, ESRD patients selected forACE-I, did not have increased rates of adverse haemodynamic or arrhythmic complications and the use of ACE-I conferred an independent mortality reduction over long-term follow-up.
Dilated cardiomyopathy in dialysis patients--beneficial effects of carvedilol: a double-blind, placebo-controlled trial.
A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.
TLDR
Long-term treatment with trandolapril in patients with reduced left ventricular function soon after myocardial infarction significantly reduced the risk of overall mortality, mortality from cardiovascular causes, sudden death, and the development of severe heart failure.
...
...